![]() |
Volumn 98, Issue 15, 2001, Pages 8897-8902
|
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2 (ACETYLOXY)BENZOIC ACID 3 (NITROOXYMETHYL) PHENYL ESTER;
CARBON TETRACHLORIDE;
COLLAGEN;
N ACETYL S NITROSOPENICILLAMINE;
NCX 1000;
NITRATE;
NITRIC OXIDE DONOR;
NITRIC OXIDE SYNTHASE;
NITRITE;
PHENOBARBITAL;
UNCLASSIFIED DRUG;
URSODEOXYCHOLIC ACID DERIVATIVE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
CHRONIC LIVER DISEASE;
CONTROLLED STUDY;
DRUG MECHANISM;
LIVER CIRRHOSIS;
LIVER FIBROSIS;
MALE;
MICROCIRCULATION;
NONHUMAN;
PORTAL HYPERTENSION;
PRIORITY JOURNAL;
RAT;
SCAR;
WOUND CONTRACTION;
ANIMALS;
CARBON TETRACHLORIDE;
COLLAGEN;
HYPERTENSION, PORTAL;
LIVER;
LIVER CIRRHOSIS;
MALE;
NITRATES;
NITRIC OXIDE;
NITRIC OXIDE DONORS;
RATS;
RATS, WISTAR;
SALICYLIC ACIDS;
URSODEOXYCHOLIC ACID;
ANIMALIA;
|
EID: 0035902558
PISSN: 00278424
EISSN: None
Source Type: Journal
DOI: 10.1073/pnas.151136298 Document Type: Article |
Times cited : (120)
|
References (33)
|